AU2023267136A1 - Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease - Google Patents

Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease Download PDF

Info

Publication number
AU2023267136A1
AU2023267136A1 AU2023267136A AU2023267136A AU2023267136A1 AU 2023267136 A1 AU2023267136 A1 AU 2023267136A1 AU 2023267136 A AU2023267136 A AU 2023267136A AU 2023267136 A AU2023267136 A AU 2023267136A AU 2023267136 A1 AU2023267136 A1 AU 2023267136A1
Authority
AU
Australia
Prior art keywords
mapt
hnrnp
tau
mrna
motoneurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023267136A
Other languages
English (en)
Inventor
Michael BRIESE
Saeede SALEHI
Michael Anton Sendtner
Abdolhossein ZARE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of AU2023267136A1 publication Critical patent/AU2023267136A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023267136A 2022-05-13 2023-03-13 Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease Pending AU2023267136A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263364629P 2022-05-13 2022-05-13
US63/364,629 2022-05-13
US202263382536P 2022-11-07 2022-11-07
US63/382,536 2022-11-07
PCT/EP2023/056392 WO2023217437A1 (en) 2022-05-13 2023-03-13 Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2023267136A1 true AU2023267136A1 (en) 2024-10-10

Family

ID=85685250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023267136A Pending AU2023267136A1 (en) 2022-05-13 2023-03-13 Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease

Country Status (6)

Country Link
US (1) US20250304958A1 (https=)
EP (1) EP4522217A1 (https=)
JP (1) JP2025517123A (https=)
AU (1) AU2023267136A1 (https=)
CA (1) CA3246379A1 (https=)
WO (1) WO2023217437A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
AU2021238319A1 (en) * 2020-03-18 2022-10-06 University Of Massachusetts Oligonucleotides for MAPT modulation

Also Published As

Publication number Publication date
JP2025517123A (ja) 2025-06-03
CA3246379A1 (en) 2023-11-16
WO2023217437A1 (en) 2023-11-16
EP4522217A1 (en) 2025-03-19
US20250304958A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
Litvinchuk et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model
Long et al. Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease
Gupta et al. miRNAs in Alzheimer disease–a therapeutic perspective
US20230257743A1 (en) Use of p38 inhibitors to reduce expression of dux4
Perez et al. Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia
EP3362564B1 (en) Nucleic acid based tia-1 inhibitors
TW201733597A (zh) 用於減少tau表現之組合物及方法
US20210123051A1 (en) Uses for prevention or treatment of brain diseases using microrna
JP2018531046A6 (ja) 核酸ベースのｔｉａ−１阻害剤
US20250059535A1 (en) Opa1 antisense oligomers for treatment of conditions and diseases
WO2019229133A1 (en) Methods of treating or preventing an aging-related disease
US20170246200A1 (en) Microrna-132/212 for the treatment of neurodegenerative disorders
Gao et al. The mechanisms underlying TDP-43-associated neurodegeneration in Alzheimer’s disease and related dementias
US12584133B2 (en) Antisense nucleic acid and use thereof
US20250304958A1 (en) Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease
US12565650B2 (en) STAUFEN1 regulating agents and associated methods
Ahammad et al. Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy Evaluation
US20200069721A1 (en) Staufen1 agents and associated methods
KR20190051510A (ko) miR-485-3p를 이용한 알츠하이머병 진단 방법
Sun et al. Significant downregulation of Alzheimer's amyloid-β levels enabled by engineered DNA nanomaterials
US20260083766A1 (en) Methods to treat neurodegenerative disorders by reducing nuclear aggregates and modulating adenosine-to-inosine rna editing
Ahammad et al. Peptide-Mediated Delivery of α-Synuclein Targeting ASO: Pharmacokinetics, Safety, and CNS Efficacy in a Synucleinopathy Model
CN121420062A (zh) 反义治疗
Mori et al. RPL38 controls 60S ribosomal subunit homeostasis to regulate start-codon stringency and frame selection during C9ORF72 RAN translation
WO2024160756A1 (en) Suppressors of tauopathies